안구건조증 시장 규모, 점유율, 동향 및 예측 : 질환 유형, 약물 유형, 제품 유형, 유통 채널, 지역별(2026-2034년)

The global dry eye syndrome market size was valued at USD 5.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 8.0 Billion by 2034, exhibiting a CAGR of 4.83% during 2026-2034. North America currently dominates the market, holding a significant market share of over 55.0% in 2025 . The high geriatric population, rising screen time among people of various age groups, increasing environmental pollution, and the growing consumer healthcare spending are some of the major factors propelling the market growth in North America.

The increasing incidence of eye-related illnesses, especially among the elderly population, which is more vulnerable to long-term ailments like dry eyes, represents one of the key factors supporting the growth of the market. Dry eye symptoms are becoming more common in several age groups as a result of increased screen time brought on by the widespread use of digital gadgets and environmental variables like pollution and arid regions. In addition, the market is expanding because of advancements in therapeutic solutions and diagnostic tools, such as novel prescription eye drops, artificial tears, and medical gadgets. Early identification and treatment are also being encouraged by rising healthcare costs and increasing awareness about eye health.

The United States stands out as a key market disruptor, driven by high prevalence of eye-related disorders, especially in its elderly population, with a notable proportion of those 50 years of age and older exhibiting symptoms. Digital eye strain is a significant risk factor for dry eye syndrome, and its prevalence is increasing due to the extensive use of digital devices, remote work patterns, and excessive screen time. The illness is getting worse by environmental factors, such air pollution and the extensive use of air conditioners (ACs). The adoption of cutting-edge diagnostic and treatment solutions is facilitated by the United States' strong healthcare system and widespread insurance coverage for eye care. Early diagnosis and treatment are also being encouraged by expanding education programs and awareness efforts run by groups like the American Optometric Association (AOA). The IMARC Group's report shows that the United States dry eye syndrome market is expected to reach US$ 3.8 Billion by 2032.

DRY EYE SYNDROME MARKET TRENDS:

Rising Geriatric Population

The increasing geriatric population is an important driver for the market growth around the world. Dry eye syndrome is more common in the geriatric population due to the natural aging process, which impacts the eye's ability to produce sufficient tears. Furthermore, countries across the globe are experiencing an increase in life expectancy, which, in turn, is increasing the geriatric population. This shift has a direct impact on the prevalence of age-related medical conditions, including dry eye syndrome. Besides this, geriatric adults are more susceptible to chronic health illnesses, and medications used for these conditions often have side effects that exacerbate dry eye symptoms. As a result, healthcare systems are facing an increased demand for both diagnostic services and treatments for dry eye syndrome, such as lubricating eye drops, prescription medications, and specialized eye care services.

Increasing Screen Time

The rising screen time among various age groups is a substantial factor fueling the market growth. Office workers spend an average of 6.5 hours each day in front of computer screens or laptops, excluding time spent on mobile devices at work. Additionally, Americans average nearly 11 hours of screen time per day, with the majority occurring during work hours. Modern lifestyles are dependent on digital screens, such as smartphones, tablets, and computer monitors. Furthermore, the emerging remote working culture is extending the exposure of employees to digital screens, which decreases the frequency of blinking, causing dryness in the eyes. Besides this, several studies are indicating a strong association between heightened screen time and symptoms of dry eye syndrome among young adults. Therefore, the escalating need for treatments targeting digital eye strain-induced dry eye is contributing to increased consumer spending on over the counter (OTC) artificial tears, prescription treatments, and devices designed to reduce digital eye strain.

Growing Environmental Pollution

Environmental factors also play an important role in the expansion of the dry eye syndrome market. The WHO estimates that approximately 90% of the global population is exposed to polluted air. Polluted air and extreme weather conditions in rapidly industrializing regions are exacerbating the symptoms of dry eye syndrome. In line with this, air pollution particles cause irritation and are often toxic to the eye's delicate tissues, thereby inducing or aggravating dry eye symptoms. Furthermore, various indoor pollutants, including volatile organic compounds (VOCs) emitted from cleaning products, paints, and other household items, reduce indoor air quality and lead to eye irritation and dryness. Besides this, allergic reactions from polluted environments can trigger dry eye symptoms in individuals who are susceptible to allergies. Moreover, environmental pollution contributes to climate change, which can alter weather patterns and humidity levels. These changes significantly affect tear evaporation rates and exacerbate dry eye symptoms, especially in arid regions.

DRY EYE SYNDROME INDUSTRY SEGMENTATION:

Analysis by Disease Type:

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome

Evaporative dry eye syndrome leads the market with around 75.5% of market share in 2025. Due to its complex character and high incidence, evaporative dry eye syndrome (EDES) is the most common illness category. This illness is made worse by modern lifestyle choices like extended use of digital screens, increasing reliance on air conditioning (AC), and exposure to contaminants in the environment. Owing to physiological changes in gland function and tear production, the elderly population, a major demographic for eye disorders, is particularly vulnerable to EDES. Because the condition is chronic, it must be managed on time, which is driving the demand for therapeutic options like anti-inflammatory drugs, artificial tears, and cutting-edge therapies like thermal pulsation devices. Additionally, rising diagnosis rates owing to advancements in diagnostic technology and greater awareness about eye health are making EDES a common eye syndrome worldwide.

Analysis by Drug Type:

• Anti-inflammatory Drugs
• Lubricant Eye Drops
• Autologous Serum Eye Drops

Anti-inflammatory drugs lead the market with around 53.3% of market share in 2025. As inflammation is a major contributing element to many eye problems, anti-inflammatory medications are the most common type of drugs in the market. Inflammation frequently aggravates symptoms and prevents recovery in conditions, such as dry eye syndrome, uveitis, and allergic conjunctivitis. These medications, which include cyclosporine, corticosteroids, and nonsteroidal anti-inflammatory medicines (NSAIDs), provide quick symptom relief by efficiently reducing discomfort, swelling, and redness. The need for anti-inflammatory therapy is increasing due to the rising incidence of chronic eye problems associated with age, extended screen time, and environmental irritants. Furthermore, improvements in medication formulations like sustained-release and preservative-free choices, are improving therapeutic results and patient compliance. Their market share is further supported by the growing awareness among the masses about eye health issues and the accessibility of both prescription and over-the-counter (OTC) anti-inflammatory medications.

Analysis by Product:

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others

Liquid drops lead the market with around 59.3% of market share in 2025. Because of the versatility, effectiveness, and ease of use of liquid drops for a wide range of eye problems, they are the most popular product category in the eye syndrome market. Patients prefer liquid drops as a non-invasive solution for instant symptom alleviation, especially for dryness, irritation, and inflammation. They provide a range of products, such as antibiotic drops for infections, antihistamines for allergies, and artificial tears for dry eye condition. The need for these treatments is growing because of the rising incidence of diseases like dry eye syndrome, which are caused by environmental factors, digital screen usage, and aging populations. Furthermore, formulation developments including multi-dose vials and preservative-free alternatives are improving use and safety. Their dominance is further reinforced by their accessibility and cost, both through prescription drugs and over-the-counter (OTC).

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hospital pharmacies leads the market with around 56.3% of market share in 2025. Because they play a crucial role in delivering specialist eye care treatments and guaranteeing access to prescription pharmaceuticals, hospital pharmacies are the main distribution channel in the market for eye syndrome. They are the main source for recommended pharmaceuticals, such as antibiotics, anti-inflammatory drugs, and advanced therapies, as ophthalmologists frequently diagnose eye syndrome and develop treatment regimens for patients in hospital settings. These pharmacies have the benefit of providing quick access to necessary medications, particularly in circumstances that are urgent or severe. Hospital pharmacies are also reputable for upholding strict quality standards and providing a variety of specialty goods, such as compounded formulas for difficult situations. The dependence on hospital pharmacists is further fueled by the rising incidence of chronic eye disorders and increasing hospitalizations for diagnostic and treatment operations.

Regional Analysis:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

In 2025, North America accounted for the largest market share of over 55.0%. Owing to its sophisticated healthcare system, high incidence of eye conditions, and substantial expenditure in R&D, North America dominates the market for eye syndrome. The prevalence of diseases like dry eye syndrome is increasing in the region due to aging population, widespread use of digital screens, and environmental factors like pollution and air conditioning (AC). Furthermore, North America has a robust network of hospitals and clinics that specialize in ophthalmology, which facilitates prompt diagnosis and treatment. The market is further driven by the existence of top pharmaceutical businesses and continuous advancements in eye care goods like sophisticated treatments and diagnostic instruments. A significant part is also played by high healthcare costs, extensive insurance coverage, and heightened public awareness about eye health.

KEY REGIONAL TAKEAWAYS:

UNITED STATES DRY EYE SYNDROME MARKET ANALYSIS

In 2025, the dry eye syndrome market in the United States accounts for over 89% of the North American market share. It is drive by the high prevalence of dry eye disease , advanced healthcare infrastructure, and considerable R&D investment. Pharmaceutical innovations, including FDA-approved treatments like Xiidra and Restasis, are propelling the market growth. Telemedicine platforms are increasingly used for diagnosis and treatment of the condition. Further government initiatives, such as the National Eye Institute funding for research related to vision further fortify this market. Key players, such as Allergan and Novartis, are pushing ahead with the development of new therapies, including the latter's FDA-approved CEQUA, which is bolstering the growth of the market.

EUROPE DRY EYE SYNDROME MARKET ANALYSIS

Rising cases throughout Europe owing to an aging demography and increased screen time are positively influencing the European dry eye syndrome market. The EU's regulatory frameworks like CE Mark approval are facilitating the availability of novel therapies, including CEQUA, which entered the market in 2020. Awareness campaigns, such as those promoted by the European Dry Eye Society, call for early diagnosis and management. New diagnostic technologies, including the TearLab Osmolarity System, are being adopted for more precise assessments. Companies including Santen and Thea are expanding portfolios in preservative-free eye drops, long-term patient safety considerations, thereby strengthening the market growth.

ASIA PACIFIC DRY EYE SYNDROME MARKET ANALYSIS

The dry eye syndrome market in Asia Pacific is growing owing to factors like urbanization, lifestyle, and high health-care investment. Japan emerges as a significant market because of the aging population and advanced stages of health-care technologies. Demand for eye care service in China is increasing because of several factors including a demographic trend of aging population and high levels of eye diseases. Japan has been setting out its Vision 2030 to improve ophthalmologic care, while in China, the National Medical Products Administration is giving approval to newer treatments. Wearable diagnostics, along with health applications via mobiles, are helping tailor treatment for each individual, which is impelling the market growth.

LATIN AMERICA DRY EYE SYNDROME MARKET ANALYSIS

Latin America's dry eye syndrome market is expanding due to increased healthcare accessibility and the rising prevalence of chronic conditions. The adoption of teleophthalmology is rising, especially in remote areas, improving diagnosis and subsequent follow-up. International patients are attracted to Costa Rica, where it is possible to receive treatment for dry eye, a big earner for local medical tourism providers. Allergan's Restasis has a broad foothold in the market, although local makers were believed to be developing low-cost generic alternatives.

MIDDLE EAST AND AFRICA DRY EYE SYNDROME MARKET ANALYSIS

Dry eye syndrome in the Middle East and Africa is growing due to increasing investments in health and an increasing prevalence of the disease in dry climatic zones. Non-governmental organizations, such as Orbis International work alongside governments in Africa to make eye care more accessible. For example, in Ethiopia, in 2023, Orbis administered more than 8.8 million doses of the antibiotic azithromycin as part of efforts to eliminate trachoma, an infectious disease that can cause blindness. Meanwhile, they conducted more than 400,000 community eye screenings and examinations, attracting more than 192,000 patients for eye care services. Telemedicine is also highly adopted here, which presents challenges in rural areas and encourages early diagnosis.

COMPETITIVE LANDSCAPE:

Leading players are investing in creating new formulations, devices, and treatment methods to address different forms of dry eye syndrome more effectively. Furthermore, they are working with research institutions, other pharmaceutical companies, and healthcare providers to accelerate the development of new products and extend their market reach. Besides this, top firms are acquiring smaller companies with innovative technologies to diversify their product portfolio quickly and gain a competitive advantage. Additionally, companies are developing educational campaigns aimed at both healthcare providers and the public to raise awareness about the importance of early diagnosis and effective treatment, which, in turn, is increasing dry eye syndrome market revenue. Moreover, they are setting up manufacturing units, expanding distribution channels, and focusing on partnerships to tap into the growing demand for dry eye treatments in various geographical regions.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Akorn Operating Company LLC
• Alimera Science
• Allergan plc.
• Auven Therapeutics
• Bausch + Lomb Incorporated
• GlaxoSmithKline plc
• Nicox S.A.
• Novartis AG
• Otsuka Holdings Co., Ltd.
• Santen Pharmaceutical Co., Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is dry eye syndrome?

2. How big is the dry eye syndrome market?

3. What is the expected growth rate of the global dry eye syndrome market during 2026-2034?

4. What are the key factors driving the global dry eye syndrome market?

5. What is the leading segment of the global dry eye syndrome market based on the disease type?

6. What is the leading segment of the global dry eye syndrome market based on drug type?

7. What is the leading segment of the global dry eye syndrome market based on product?

8. What is the leading segment of the global dry eye syndrome market based on distribution channel?

9. What are the key regions in the global dry eye syndrome market?

10. Who are the key players/companies in the global dry eye syndrome market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Dry Eye Syndrome Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Disease Type
• 5.5 Market Breakup by Drug Type
• 5.6 Market Breakup by Product
• 5.7 Market Breakup by Distribution Channels
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Evaporative Dry Eye Syndrome
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Aqueous Dry Eye Syndrome
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Anti-inflammatory Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Lubricant Eye Drops
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Autologous Serum Eye Drops
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Product

• 8.1 Liquid Drops
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Gel
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Liquid Wipes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Eye Ointment
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Online Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Global Dry Eye Syndrome Industry: SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Global Dry Eye Syndrome Industry: Value Chain Analysis

13 Global Dry Eye Syndrome Industry: Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Global Dry Eye Syndrome Industry: Price Analysis

• 14.1 Price Indicators
• 14.2 Price Structure
• 14.3 Margin Analysis

15 Manufacturing Process

• 15.1 Product Overview
• 15.2 Raw Material Requirements
• 15.3 Manufacturing Process
• 15.4 Key Success and Risk Factors

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Akorn Operating Company LLC
  • 16.3.2 Alimera Science
  • 16.3.3 Allergan plc.
  • 16.3.4 Auven Therapeutics
  • 16.3.5 Bausch + Lomb Incorporated
  • 16.3.6 GlaxoSmithKline plc
  • 16.3.7 Nicox S.A.
  • 16.3.8 Novartis AG
  • 16.3.9 Otsuka Holdings Co., Ltd.
  • 16.3.10 Santen Pharmaceutical Co., Ltd.